PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

  1. Rincón, R.
  2. Cristóbal, I.
  3. Zazo, S.
  4. Arpí, O.
  5. Menéndez, S.
  6. Manso, R.
  7. Lluch, A.
  8. Eroles, P.
  9. Rovira, A.
  10. Albanell, J.
  11. García-Foncillas, J.
  12. Madoz-Gúrpide, J.
  13. Rojo, F.
Aldizkaria:
Oncotarget

ISSN: 1949-2553

Argitalpen urtea: 2015

Alea: 6

Zenbakia: 6

Orrialdeak: 4299-4314

Mota: Artikulua

DOI: 10.18632/ONCOTARGET.3012 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus